Zimbabwe has rejected a significant US health deal valued at $367m (272 million pounds) spanning five years due to the United States' demand for confidential biological samples.
This move came to light following a government memo from December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government spokesman later explained that the United States was demanding access to biological samples for scientific study and profit while was not willing to guarantee the resulting advantages from future vaccines.
"We must now begin the difficult and regrettable process of ending our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had donated more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for more negotiations to find a agreement suitable to all parties so the country's critical HIV programme can be sustained.
Wider Background
Zimbabwe's decision follows a similar case in neighbouring Kenya, where a high court blocked a similar health funding agreement after legal challenges were filed about the safety of Kenyans' health data.
Since resuming the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had administered assistance for the American government, but Trump stated its spending was "inefficient" and his government was seeking direct bilateral deals to enhance openness and accountability.
According to reports, Sixteen African countries have so far signed similar health pacts, representing over $18.3bn of fresh investment.
Details of the Declined Agreement
The funds for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million currently receiving HIV treatment via US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"The proposal required Zimbabwe to provide its biological resources and data for a long time, with no equivalent promise of access to any medical innovations – like new medicines or tests – that could be developed from that shared data," his statement read.
"Effectively, our country would supply the raw materials for scientific discovery without any certainty that the end products would be accessible to our people should a future health crisis arise."
National Interest and Global Health
Mangwana further said that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were undermining structures previously established via the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to manage potential global health emergencies.
"This mechanism is intended to ensure that when a country contributes its data, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
These objections over the US deal "are not meant as opposition to America," he added.
"We welcome continued dialogue with our US partners on how subsequent collaboration might be arranged in a manner that respects the sovereignty and dignity of each country."
Medical Community Response
A leading public health body said it understood the official position, but urged that talks should continue considering a large portion of the nation's Aids initiatives were funded by foreign aid.
"If technical issues exist, such as those relating to information security or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," the group said.
The halted deal highlights the complex tensions between receiving vital international aid and protecting a country's data in an increasingly data-driven world.